Grants and Contributions:
Title:
Development of novel radiopharmaceuticals for the treatment of prostate cancer
Agreement Number:
982291
Agreement Value:
$344,000.00
Agreement Date:
Jul 1, 2021 - Mar 31, 2023
Description:
This project will support the pre-clinical development of novel therapeutic radiopharmaceuticals that selectively bind to prostate-specific membrane antigen (PSMA), as potential treatments for prostate cancer.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Vancouver, British Columbia, CA V5T 1M4
Reference Number:
172-2021-2022-Q4-982291
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
776454530
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The total amended value is 44,000 dollars.
Amendment Date
Jan 24, 2023
Recipient's Legal Name:
Alpha-9 Theranostics Inc.
Federal Riding Name:
Vancouver East
Federal Riding Number:
59035
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
54171
Amendments: